Company: JUNS
Filing Date: 2025-03-28
Form Type: 10-K
Source: 0001641172-25-001261
Chunk: 1542

Company: JUPITER NEUROSCIENCES, INC.
Filing Date: 2025-03-28
Form: 10-K
Item: Item 7
Chunk 1542
---

enhanced orally administered resveratrol formulation designed and intended to deliver therapeutically relevant, safe levels of resveratrol.
This platform has many potential indications of use for rare diseases, which include Mucopolysaccharidoses Type 1, Friedreich’s
ataxia and MELAS. In the larger disease areas, we are primarily targeting Parkinson’s Disease and Mild Cognitive Impairment/early
Alzheimer’s disease.

The present primary target for the Company is
treatment of Parkinson’s Disease (PD). The Company completed preclinical activities in a validated mouse model of
Parkinson’s Disease (PD) at the University of Miami in 2021. See our “Clinical Studies”. The model of
Parkinson’s Disease that was used in this preclinical study mimics many aspects of the disease utilizing a unilateral
injection of a neurotoxin precursor that elicits nigral cell loss, striatal dopamine loss and behavior deficits similar to
physiological characteristics of human disease. We believe that results from this preclinical study indicate that Parkinson’s
Disease might be the best target for treatment and financial opportunity among the multiple indications where JOTROL might play a
role. The Company is now in the process to start its first Phase II clinical trial in a patient population. This will be a Phase IIa
study conducted with the assistance of Zina Biopharmaceuticals that is led by Dr. Charbel Moussa, MBBS,Ph.D. The study is expected
to start in the third quarter of 2025 and have results available approximately 12 months thereafter.

We are also targeting the treatment of MCI/early
Alzheimer’s Disease. We received funding of $2.2 million from the National Institute of Aging (“NIA”) in in 2020 and
2022 from a grant application for a Phase 1 study for Mild Cognitive Impairment/ Alzheimer’. In the NIA scientific review summary
statement of our Phase I study application, it is stated that the NIA is looking forward to a Phase II study with an enhanced resveratrol
product, based on the earlier study results from the well published Turner et al. Alzheimer’s study. We presently have a pending
grant application, $16.5 Million, for a Phase II trial in MCI/early Alzheimer’s Disease with the NIA. This is an application for
a 3-year Phase II trial that is expected to be completed with approximately 100 patients that have Mild